Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial

(2015) Wolfgang Kothny et al.   DIABETOLOGIA

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

(2015) Faiez Zannad et al.   LANCET

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

(2015) Jennifer B. Green et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials

(2014) Nayyar Iqbal et al.   Cardiovascular Diabetology

Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Outcomes: Meta-Analysis of Randomized Clinical Trials with 55,141 Participants

(2014) Shiying Wu et al.   Cardiovascular Therapeutics

Incretin-Based Drugs and the Risk of Congestive Heart Failure

(2014) Oriana Hoi Yun Yu et al.   DIABETES CARE

Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus

(2014) Gillian M. Keating   DRUGS

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

(2014) Rury R Holman et al.   LANCET

Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials

(2014) M. Monami et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus 中国2型糖尿病患者使用磺脲类药物联合维格列汀可改善血糖控制且无低血糖及体重增加

(2014) Wenying Yang et al.   Journal of Diabetes

Do Dipeptidyl Peptidase-4 Inhibitors Increase the Risk of Heart Failure? ∗

(2014) Deepak L. Bhatt et al.   JACC-Heart Failure

Sitagliptin Use in Patients With Diabetes and Heart Failure

(2014) Daniala L. Weir et al.   JACC-Heart Failure

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus

(2014) Masato Odawara et al.   Diabetes Therapy

Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS)

(2013) Eyal Leibovitz et al.   Cardiovascular Diabetology

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea

(2013) V. Lukashevich et al.   DIABETES OBESITY & METABOLISM

Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study

(2013) W David Strain et al.   LANCET

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

(2012) Odd Johansen et al.   Cardiovascular Diabetology

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus

(2012) C. Pan et al.   DIABETES OBESITY & METABOLISM

One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment

(2012) W. Kothny et al.   DIABETES OBESITY & METABOLISM

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

(2012) M. Monami et al.   DIABETES OBESITY & METABOLISM

Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus

(2012) W. Kothny et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial

(2011) V. Lukashevich et al.   DIABETES OBESITY & METABOLISM

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial

(2011) J. E. Foley et al.   DIABETOLOGIA

Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study

(2010) Y. Iwamoto et al.   DIABETES OBESITY & METABOLISM

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

(2010) D. R. Matthews et al.   DIABETES OBESITY & METABOLISM

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

(2010) A. Schweizer et al.   DIABETES OBESITY & METABOLISM

Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus

(2010) Masatoshi Kikuchi et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

(2010) C. Filozof et al.   DIABETIC MEDICINE

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

(2010) The Emerging Risk Factors Collaboration   LANCET

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

(2010) Debora Williams-Herman et al.   BMC Endocrine Disorders

Trends in All-Cause and Cardiovascular Disease Mortality Among Women and Men With and Without Diabetes Mellitus in the Framingham Heart Study, 1950 to 2005

(2009) Sarah Rosner Preis et al.   CIRCULATION

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin

(2009) G. Bolli et al.   DIABETES OBESITY & METABOLISM

Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus

(2009) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial

(2009) A. Schweizer et al.   DIABETES OBESITY & METABOLISM

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

(2009) E. Ferrannini et al.   DIABETES OBESITY & METABOLISM

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus

(2009) E. Bosi et al.   DIABETES OBESITY & METABOLISM

Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus

(2009) Masatoshi Kikuchi et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Efficacy and Tolerability of Vildagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy

(2009) M. Goodman et al.   HORMONE AND METABOLIC RESEARCH

Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naïve Patients with Type 2 Diabetes

(2009) J. E. Foley et al.   HORMONE AND METABOLIC RESEARCH

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia*

(2008) W. A. Scherbaum et al.   DIABETES OBESITY & METABOLISM

Efficacy and tolerability of vildagliptin in drug-nave patients with type 2 diabetes and mild hyperglycaemia

(2008) W. A. Scherbaum et al.   DIABETES OBESITY & METABOLISM

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea*

(2008) A. J. Garber et al.   DIABETES OBESITY & METABOLISM

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial

(2008) C. Pan et al.   DIABETIC MEDICINE

Efficacy and Safety of Vildagliptin Monotherapy during 2-Year Treatment of Drug-naïve Patients with Type 2 Diabetes: Comparison with Metformin

(2008) B. Göke et al.   HORMONE AND METABOLIC RESEARCH

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Characterization of the Influence of Vildagliptin on Model-Assessed β-Cell Function in Patients with Type 2 Diabetes and Mild Hyperglycemia

(2007) Andrea Mari et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM